Identify Clinical Conditions That Increase Circulating DNA Levels
NCT ID: NCT01815996
Last Updated: 2018-11-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
130 participants
OBSERVATIONAL
2012-10-31
2016-07-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Many diseases and medical conditions can put DNA in the blood. The investigator needs to know how much DNA in order to better interpret our radiation detection test. Therefore, the investigator is collecting blood from several patients with different diseases or medical conditions and also healthy volunteers to measure their DNA content.
Patients that will be included in this study are pregnant women, patients who have suffered a pulmonary embolism within the past 48 hours, patients who have suffered from myocardial infarction in the past 48 hours, patients with autoimmune diseases and health patients.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Rare and Undiagnosed Disease Research Biorepository
NCT04703179
NIEHS Repository of Stored Biological Samples for Future Use
NCT05666739
Molecular and Clinical Studies of Primary Immunodeficiency Diseases
NCT00006319
BioGene Bank Cohort Study for Approved Research Requests
NCT02550171
Genetic Analysis of Immune Disorders
NCT00001467
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pregnant Women
Females between the age of 18-80 who are pregnant
One time blood draw to look at patient's DNA
One time blood draw to look at patient's DNA
One time blood draw to look at patient's DNA
Pulmonary Embolism Patients
Male and Female patients that have suffered a pulmonary embolism within the past 48 hours
One time blood draw to look at patient's DNA
One time blood draw to look at patient's DNA
One time blood draw to look at patient's DNA
Myocardial Patients
Male and Female patients who have myocardial infarction in the past 48 hours.
One time blood draw to look at patient's DNA
One time blood draw to look at patient's DNA
One time blood draw to look at patient's DNA
Autoimmune Patients
Male and Female patients that have been diagnosed with an Autoimmune disease
One time blood draw to look at patient's DNA
One time blood draw to look at patient's DNA
One time blood draw to look at patient's DNA
Healthy Controls
Self-declared healthy adults (men and women).
One time blood draw to look at patient's DNA
One time blood draw to look at patient's DNA
One time blood draw to look at patient's DNA
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
One time blood draw to look at patient's DNA
One time blood draw to look at patient's DNA
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Pregnant
* Suffered a pulmonary embolism within the past 48 hours
* Myocardial infarction in the past 48 hours
* Diagnosed with an autoimmune disease
* Adults age 18-80
* Self-declared healthy adults
2. Patients must be willing to undergo a blood draw
3. Patients must provide study-specific informed consent prior to study entry
18 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Florida
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Paul Okunieff, MD
Role: PRINCIPAL_INVESTIGATOR
University of Florida
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shands Davis Cancer Center
Gainesville, Florida, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB201702171
Identifier Type: OTHER
Identifier Source: secondary_id
407-2012
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.